Home     Site Map     Legal   

  Latest News
  Archive

September 19, 2012 MBC Pharma and Maxwell Biotech Group partner to clinically develop a new anti-tumor drug candidate MBC-11 targeting metastatic bone disease (read more)
May 25, 2012 MBC Pharma, Inc. wins a legal battle against Cedarburg Hauser Pharmaceuticals (read more)











  Recent Publications
  1. Reinholz, M. M., Zinnen, S. P., Dueck, A. C., Dingli, D., Reinholz, G. G., Jonart, L. A., Kitzmann, K. A., Bruzek, A. K., Negron, V., Abdalla, A. K., Arendt, B. K., Croatt, A. J., Sanchez-Perez, L., Sebesta, D. P., Lonnberg, H., Yoneda, T., Nath, K. A., Jelinek, D. F., Russell, S. J., Ingle, J. N., Spelsberg, T. C., Dixon, H. B., Karpeisky, A., Lingle, W. L., (2010),A promising approach for treatment of tumor-induced bone diseases: Utilizing bisphosphonate derivatives of nucleoside antimetabolites Bone , 47 73, 12-22
  2. Mikko Ora, Tuomas Lonnberg, Diana Florea-Wang, Shawn Zinnen,Alexander Karpeisky, and Harri Lonnberg (2008)  Bisphosphonate Derivatives of Nucleoside Antimetabolites:
    Hydrolytic Stability and Hydroxyapatite Adsorption of 5′-b,γ-Methylene and 5′-b,γ-(1-Hydroxyethylidene) Triphosphates of 5-Fluorouridine and ara-Cytidine. JOC, 73, 4123-30
  3. Zinnen, S.,Sebesta, D., Karpeisky, A., Guzaev, A., (2006) Novel vitamin B6 derivative of alendronate rapidly absorbed following oral administration. Bone 38, S64
  4. Reinholz, M., Reinholz, G., Arendt, B., Jelinek, D., Kitzmann, K., Dingli, D., Russel, S., W., L., and Karpeisky, A. (2005). Novel bisphosphonate conjugates inhibit multiple myeloma cell proliferation in vitro and increase bone mineral density and prolong survival in a mouse multiple myeloma model. Cancer Treatment Reviews 31, abstract # 119.
  5. Reinholz, M., Reinholz, G., Jonart, L., Yoneda, T., Spelsberg, T., Lingle, W., and Karpeisky, M. (2004). Novel bisphosphonate conjugates decrease metastatic bone tumor burden in the 4T1/luc mouse model of breast cancer. Journal of Bone and Mineral Research 19, S66.
  6. Reinholz, M., Jonart, L., Reinholz, G., Spelsberg, T., Lingle, W., Yoneda, T., and Karpeisky, M. (2004). The effects of novel bisphosphonate conjugates on primary breast tumor burden and soft organ metastases in the 4T1/luciferase mouse model of breast cancer. Breast Cancer Research and Treatment 88, S133.
  7. Reinholz, G.G., Getz, B., Sanders, E.S., Karpeisky, M.Y., Padyukova, N., Mikhailov, S.N., Ingle, J.N., and Spelsberg, T.C. (2002). Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue. Breast Cancer Research and Treatment 71, 257-268


MBC Pharma, Inc.   12635 E. Montview Blvd., Suite 100  Aurora, CO 80045
Phone: 720-859-4041  Fax: 303-484-3532
Email: information@mbcpharma.com